C17orf45 Inhibitors

Compounds like Staurosporine, LY294002, and Rapamycin act on kinases and kinases-related pathways such as PI3K/AKT and mTOR, which are central to cell growth and survival, and could thus indirectly affect C17orf45 activity if it is a part of or regulated by these pathways. SB203580 and PD98059 are inhibitors of the MAPK signaling pathway, which is involved in cell proliferation, differentiation, and stress responses, and could have an impact on C17orf45 if it is regulated by this pathway.

MG132 and Bortezomib are proteasome inhibitors that prevent the degradation of proteins, which may stabilize C17orf45 if it is normally marked for degradation. Thapsigargin and 2-Deoxy-D-glucose disrupt calcium homeostasis and glycolysis, respectively, and could influence C17orf45 activity if it is associated with calcium signaling or cellular metabolism. U0126, like PD98059, targets the MEK/ERK pathway and could have implications for C17orf45 regulation. ZM-447439 inhibits Aurora kinases, which could affect C17orf45 if it has a role in cell cycle control.